Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
13 December 2024 | Story Martinette Brits | Photo Stephen Collett
Dr Francois Jacobs
Dr Francois Jacobs received his Doctor of Philosophy degree in Chemistry on Monday, 9 December.

Dr Francois Jacobs, a 30-year-old PhD graduate, has recently returned from an intensive training workshop in Harwell, Oxford, courtesy of the David Blow Bursary. This prestigious award recognises outstanding African researchers making significant contributions to macromolecular crystallography.

Dr Jacobs earned his Doctor of Philosophy degree in Chemistry on Monday, 9 December. While earning a PhD by the age of 30 was not part of his initial plan, he always aspired to pursue higher education. “From a young age, I had a strong desire to study at university. Once I got there, my ambition shifted towards obtaining a PhD,” he says, reflecting on the journey that led to this remarkable achievement.

Groundbreaking research on cancer and antibiotics

Dr Jacobs’ research addresses some of the most pressing health challenges of our time: cancer and antibiotic resistance. Using crystallography, he investigates the interactions between newly developed anticancer and antibacterial compounds and biological structures such as proteins at the atomic level. This work is vital in combating the growing threat of antibiotic-resistant bacterial infections and advancing cancer treatments.

"For me, it's about seeing humans thrive and reducing the suffering caused by illness," he explains. "I lost my grandmother to cancer, and I hope my work can spare someone else’s loved one from a similar loss."

Prestigious workshop with global experts

The "DLS-CCP4 Data Collection and Structure Solution Workshop," hosted by Diamond Light Source, offered Dr Jacobs an unparalleled opportunity to learn from leading experts in macromolecular crystallography. The workshop covered critical skills such as growing protein and DNA crystals, preventing degradation during data collection, and processing complex data. Participants also gained insights directly from the engineers and scientists behind the facility’s cutting-edge software and synchrotron technology.

“It was an incredible opportunity to learn from some of the brightest minds in the field,” says Dr Jacobs. “Not only did I acquire new skills, but I also forged new collaborations with potential research partners who can help take my work to the next level.”

The David Blow Bursary, which enabled Dr Jacobs to attend this workshop, is awarded to  African researchers conducting impactful macromolecular crystallography studies.

"This training has been transformative," he adds. "It is a fantastic experience for any aspiring researcher, and I’m grateful to have had the chance to learn from these experts. Many researchers who attend workshops like this go on to work at the Diamond Light Source itself. I am eager to see where this training will take me."

A vision for the future

As Dr Jacobs continues his research, he remains driven by the hope that his work will lead to life-saving advancements in healthcare. “I want my research to provide hope and solutions for individuals battling cancer and bacterial infections,” he says.

His achievements exemplify the transformative power of education, research, and collaboration, and his story serves as an inspiration to aspiring researchers across Africa. 

News Archive

UFS researcher explores the future cost of cancer
2017-01-10

 Description: 001 Dr Alicia Sherriff Tags: 001 Dr Alicia Sherriff

Dr Alicia Sherriff, Head the Department of Oncology
at the UFS Faculty of Health Sciences, co-authored
an article in the South African Medical Journal.

Photo: Charl Devenish

Cancer is on an exponential rise globally, and the cost of treatment is a growing international problem. South Africa alone is expected to see a 78% increase in cancer cases. Dr Alicia Sheriff, Head of the Department of Oncology, collaborated on and co-authored a research paper for the South African Medical Journal on the future of oncology treatment in the country, along with doctors from various universities across South Africa. The article, titled "The future cost of cancer: interdisciplinary cost management strategy", looks at the prognosis of cancer management in the country.

Cancer is on the rise

There is a visible growth of the cancer disease in the developing world. Rapidly changing lifestyles, uncontrolled urbanisation, pollution, and population ageing are some dynamics that provide a lethal cocktail of infectious and lifestyle risk factors that leave people at a higher risk of developing cancer.

The simultaneous increase in cancer incidence has increased the cost of treatment exponentially. The cost of cancer treatment is multitiered, making the provision of care for cancer patients a high-risk business. A combination of treatment delays, limited resources, differently skilled personnel, high patient volumes and advanced disease stage on presentation all place a bigger burden on the delivery of optimal cancer care outcomes.

Adoption of new strategies

According to the doctors, innovative thinking to embrace technology, combined with a preventive approach, as well as lowering the cost of treatment drugs should be prioritised. So should the commercialisation of new technologies that will diagnose and treat cancer in its early stages. They also encourage interdisciplinary research funding in South Africa as a way to better understand the demographic and molecular dynamics of cancer in the country, along with retaining more oncologists in the public health sector.

Efficient solutions to curb cancer mortality

The doctors assert there is a need to continue to look for more efficient measures to best treat the disease, and hopefully bring about a change in mortality levels in South Africa.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept